Celina M. D’Cruz

2.6k total citations
38 papers, 1.8k citations indexed

About

Celina M. D’Cruz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Celina M. D’Cruz has authored 38 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Celina M. D’Cruz's work include Advanced Breast Cancer Therapies (10 papers), Cancer Mechanisms and Therapy (6 papers) and Liver physiology and pathology (6 papers). Celina M. D’Cruz is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), Cancer Mechanisms and Therapy (6 papers) and Liver physiology and pathology (6 papers). Celina M. D’Cruz collaborates with scholars based in United States, United Kingdom and Japan. Celina M. D’Cruz's co-authors include Jaclyn A. Biegel, Mark A. Lovell, Frederic G. Barr, Richard J. Davis, Lewis A. Chodosh, Susan E. Moody, George K. Belka, Seung I. Ha, James D. Cox and Jennifer L. Hartman and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Molecular and Cellular Biology.

In The Last Decade

Celina M. D’Cruz

38 papers receiving 1.7k citations

Peers

Countries citing papers authored by Celina M. D’Cruz

Since Specialization

Citations

This map shows the geographic impact of Celina M. D’Cruz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Celina M. D’Cruz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Celina M. D’Cruz more than expected).

Fields of papers citing papers by Celina M. D’Cruz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Celina M. D’Cruz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Celina M. D’Cruz. The network helps show where Celina M. D’Cruz may publish in the future.

Co-authorship network of co-authors of Celina M. D’Cruz

This figure shows the co-authorship network connecting the top 25 collaborators of Celina M. D’Cruz. A scholar is included among the top collaborators of Celina M. D’Cruz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Celina M. D’Cruz. Celina M. D’Cruz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial 2024 ·Annals of Oncology ·Peter Schmid, Heather L. McArthur, (unknown), Baojun Xu, (unknown), (unknown), Utkan Demirci, (unknown), Jaya Ghosh, Roberto Hegg, Hiroaki Iwata, Yamil Alonso Lopez Chuken, M. Nechaeva, Mark E. Robson, Ricardo Villalobos-Valencia, Andrew Lloyd, Celina M. D’Cruz, Andrew Foxley, Y.H. Park	5
2	Abstract PO2-19-10: CAPItello-292 Phase 3: An open-label, randomized study of capivasertib, fulvestrant, and investigator’s choice of CDK4/6 inhibitor (palbociclib or ribociclib) in HR+/HER2– advanced breast cancer 2024 ·Cancer Research ·Hope S. Rugo, Barbara Pistilli, (unknown), Celina M. D’Cruz, Christopher Gresty, Roberto Sommavilla, Dhivya R. Sudhan, Claire Miller, Ju-Young Ha, Patrick Neven	2
3	Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial. 2023 ·Journal of Clinical Oncology ·Hope S. Rugo, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortés, Henry Gómez, Xichun Hu, Hiroji Iwata, Komal Jhaveri, Sibylle Loibl, Serafín Morales, Meena Okera, (unknown), Joohyuk Sohn, Lyudmila Zhukova, (unknown), (unknown), (unknown), Celina M. D’Cruz, Nicholas C. Turner	2
4	Abstract OT-03-04: Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07) 2021 ·Cancer Research ·Fabrice André, Erika Hamilton, Sherene Loi, Peter Schmid, (unknown), Shi Yao Lu, (unknown), Celina M. D’Cruz, Pia Herbolsheimer, Komal Jhaveri	1
5	A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity 2020 ·British Journal of Pharmacology ·Rhys D.O. Jones, (unknown), Alexandra Borodovsky, Maryann San Martin, Michelle DuPont, Celina M. D’Cruz, Alwin G. Schuller, Ryan E. Henry, Evan Barry, Lillian Castriotta, Rana Anjum, (unknown), (unknown), (unknown)	6
6	Abstract OT3-01-01: BEGONIA: Phase Ib/II open-label, platform study of safety and efficacy of durvalumab, paclitaxel and other novel oncology therapy agents as first-line (1L) therapy in patients with metastatic triple negative breast cancer (mTNBC) 2019 ·Cancer Research ·Peter Schmid, (unknown), Rahul K. Lall, Celina M. D’Cruz, (unknown), (unknown)	3
7	Abstract 3572: AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models 2016 ·Cancer Research ·Justin Cidado, Minhui Shen, Michael Grondine, Scott Boiko, Haiyun Wang, Alexandra Borodovsky, Anne Marie Mazzola, (unknown), (unknown), Douglas Ferguson, (unknown), (unknown), Celina M. D’Cruz, Lisa Drew	3
8	The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models 2015 ·Clinical Cancer Research ·Alwin G. Schuller, Evan Barry, Rhys D.O. Jones, Ryan E. Henry, Melanie M. Frigault, Garry Beran, (unknown), Maureen M. Hattersley, Aaron Smith, Joanne Wilson, Stefano Cairo, Olivier Déas, Delphine Nicolle, Ammar Adam, Michael Zinda, Corinne Reimer, Stephen E. Fawell, Edwin Clark, Celina M. D’Cruz	57
9	Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors 2015 ·Molecular Cancer Therapeutics ·Barry R. Davies, (unknown), Armelle Logié, Claire Crafter, Lyndsey Hanson, Vivien N. Jacobs, Neil H. James, Philippa Dudley, Kelly Jacques, Brendon Ladd, Celina M. D’Cruz, Michael Zinda, Justin P.O. Lindemann, Makoto Kodaira, Kenji Tamura, Emma Jenkins	54
10	AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules 2015 ·Molecular Cancer Therapeutics ·Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D’Cruz, James Yates, Michael Grondine, Zoë Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina Cosulich	103
11	Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363 2015 ·Cancer Chemotherapy and Pharmacology ·James Yates, Phillippa Dudley, Jane Cheng, Celina M. D’Cruz, Barry R. Davies	10
12	395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC) 2014 ·European Journal of Cancer ·Toni K. Choueiri, Bernard Escudier, (unknown), Eric Jonasch, D.Y.C. Heng, (unknown), Hendrik‐Tobias Arkenau, (unknown), Celina M. D’Cruz, Melanie M. Frigault, (unknown), (unknown)	1
13	Singular value decomposition-based regression identifies activation of endogenous signaling pathways in vivo 2008 ·Genome biology ·Zhandong Liu, Min Wang, James V. Alvarez, Megan Bonney, (unknown), Celina M. D’Cruz, Tien-Chi Pan, Mahlet G. Tadesse, Lewis A. Chodosh	11
14	Hormone-Induced Protection against Mammary Tumorigenesis Is Conserved in Multiple Rat Strains and Identifies a Core Gene Expression Signature Induced by Pregnancy 2006 ·Cancer Research ·Collin M. Blakely, Alexander J. Stoddard, George K. Belka, Katherine D. Dugan, Kathleen L. Notarfrancesco, Susan E. Moody, Celina M. D’Cruz, Lewis A. Chodosh	80
15	Developmental stage determines the effects of MYC in the mammary epithelium 2005 ·Development ·Collin M. Blakely, (unknown), Celina M. D’Cruz, Kristina Hähn, Katherine D. Dugan, George K. Belka, Lewis A. Chodosh	43
16	Functional Microarray Analysis of Mammary Organogenesis Reveals a Developmental Role in Adaptive Thermogenesis 2002 ·Molecular Endocrinology ·Stephen R. Master, Jennifer L. Hartman, Celina M. D’Cruz, Susan E. Moody, (unknown), Seung I. Ha, James D. Cox, George K. Belka, Lewis A. Chodosh	105
17	Persistent Parity-Induced Changes in Growth Factors, TGF-β3, and Differentiation in the Rodent Mammary Gland 2002 ·Molecular Endocrinology ·Celina M. D’Cruz, Susan E. Moody, Stephen R. Master, Jennifer Hartman, (unknown), Marcin Imieliński, James D. Cox, James Wang, Seung I. Ha, (unknown), Lewis A. Chodosh	130
18	c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations 2001 ·Nature Medicine ·Celina M. D’Cruz, Edward J. Gunther, Robert Boxer, Jennifer L. Hartman, (unknown), Susan E. Moody, James D. Cox, Seung I. Ha, George K. Belka, Alexander Golant, Robert D. Cardiff, Lewis A. Chodosh	326
19	Production and Characterization of a Soluble, Active Form of Tva, the Subgroup A Avian Sarcoma and Leukosis Virus Receptor 1999 ·Journal of Virology ·John W. Balliet, Joanne F. Berson, Celina M. D’Cruz, Julie Y. Huang, (unknown), Joanna M. Gilbert, Paul Bates	41
20	Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. 1994 ·PubMed ·Richard J. Davis, Celina M. D’Cruz, Mark A. Lovell, Jaclyn A. Biegel, Frederic G. Barr	480

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact